{
  "docId": "019de077-60e9-755b-a2a9-f474a1c234cc",
  "docSlug": "c7a8fd91214a0cf2ae7cadcb747376a3",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 42,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "other",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a three-part vertical list structure to summarize clinical trial strategy.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de077-60e9-755b-a2a9-f474a1c234cc/15",
  "deckHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc",
  "deckJsonHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc.json",
  "deckAnchorHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.75,
        "x": 0.21,
        "y": 0.0035
      },
      "kind": "list",
      "text": "Key design elements largely consistent between Phase 2b and Phase 3 studies; Hamilton Anxiety Scale (HAM-A) primary outcome measure; Primary endpoint: change from baseline to Week 12; Limited changes to key inclusion/exclusion criteria; No planned change in dosing session monitoring protocol; Duration of treatment session monitoring reduced",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "123c6789-3891-4dd9-8cd7-26790e21a5e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.21,
        "y": 0.007
      },
      "kind": "list",
      "text": "Alignment with FDA on program design reached at EOP2 meeting; Study designs believed to be consistent with FDA guidance; Program initiation expected in 2H2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37d4278f-59d0-442f-b6c0-4d4164973d95",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.75,
        "x": 0.21,
        "y": 0.0016
      },
      "kind": "list",
      "text": "Two Phase 3 pivotal clinical trials in GAD; 12-week randomized, placebo-controlled primary efficacy study design; 40-week extension phase to characterize safety and define retreatment parameters",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aea58118-8fd0-439f-9173-65a99903d7c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.16,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3 clinical trial protocols; 2. Primary endpoint in Phase 2b study was change from baseline to Week 4; 3. Phase 2b study required 12-hour minimum duration of treatment session monitoring; EOP2: end of Phase 2; GAD: generalized anxiety disorder",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3a38311-7bb4-4266-a218-822c5b43125f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.55,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "MM120 for GAD | Phase 3 Program Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23e86eee-b29b-4d6a-96c2-18d0398b43bc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "9e6aabf7-a6da-4672-8971-6c2b3ea95646",
      "evidence": "list/bullet: Key design elements largely consistent between Phase 2b and Phase 3 studies; Hamilton Anxiety Scale (HAM-A) primary outcome measure; Primary endpoint: change from baseline to Week 12; Limited changes to key",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 15,
      "beatId": "7f79eae5-2e46-4d31-b209-13e74588623a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Slides 15-18 discuss phase 2 results and market potential",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}